Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 4145 record(s)

Req # A-2024-000017

Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.

Organization: Health Canada

70 page(s)
April 2024

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Req # A-2023-00119

Requesting receipts for all travel expenditures related to Minister MacAulay’s trip to Toronto from Jan. 22, 2023, to Jan. 25, 2023.

Organization: Veterans Affairs Canada

6 page(s)
April 2024

Req # A-2023-00135

Requesting receipts for all travel expenditures related to Minister MacAulay’s trip to France and the United Kingdom from Feb. 26, 2023, to March 3, 2023.

Organization: Veterans Affairs Canada

12 page(s)
April 2024

Req # A-2023-00137

Request for records regarding policies, procedures, and benefits applicable to Canadian Armed Forces member that have been injured by Covid-19 vaccine adverse events.

Organization: Veterans Affairs Canada

21 page(s)
April 2024

Req # A-2023-00141

Since its Royal Assent in 2015; what are the number of veterans hired at Veterans Affairs Canada under the 'Veterans Hiring Act' and the number of veterans that applied to a position at VAC under the 'Veterans Hiring Act', for each year (2015-Present).

Organization: Veterans Affairs Canada

2 page(s)
April 2024

Req # A-2016-000420

Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings between Celltrion (health care company) and Health Canada between September 1, 2014 and June 30, 2015.

Organization: Health Canada

299 page(s)
March 2024

Req # A-2019-001464

All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of October 1, 2018 - end of March 2019.

Organization: Health Canada

3917 page(s)
March 2024
Date modified: